-
-
-
-
-
-
-
UroGen Pharma (URGN) Tops Q2 EPS by 2c
-
-
-
-
-
-
-
UroGen settles JELMYTO patent litigation with Teva
-
-
-
-
-
-
-
Jefferies Starts UroGen Pharma (URGN) at Buy
-
-
-
-
-
-
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
-
-
-
-
-
-
UroGen Pharma (URGN) PT Lowered to $40 at H.C. Wainwright
-
-
-
-
-
-
-
H.C. Wainwright Upgrades UroGen Pharma (URGN) to Buy
-
-
-
-
-
-
-
UroGen Pharma (URGN) PT Raised to $47 at Scotiabank
-
483,861 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


